Looking Ahead to 2027-2030: Australia’s Mid-Term Device Regulatory Timetable and Readiness Checklist

1. Key takeaways

Over the next four years, Australia’s compliance pressure concentrates on three timelines: the four UDI mandatory dates (2026–2029), the three stages of hospital mandatory reporting (2026 / 2028 / 2030), and the IVD transition submission deadlines (2028 / 2029 / 2030). Companies should schedule the work separately as items that must be completed in the year in question and items requiring early preparation, so that everything does not pile up in the final year. Because the same device classes appear under all three timelines, the schedules should be consolidated into a single product-level calendar rather than managed as separate projects.

2. Legal basis

The consolidated timeline below draws its entries from the TGA decision tree, the hospital reporting guidance, the ACSQHC advisory and the legislative instruments already cited in this series. Each entry lists the date and its source, so that any date on the list can be traced back to an official document when the internal calendar is built from it.

1. 21 March 2026 — hospital mandatory reporting Stage 1 begins (Class III and Class 4 IVD; death or serious deterioration, 10 days). Basis: Act No. 10 of 2023 (C2023A00010) and F2025L00414; TGA, Reporting medical device adverse events by healthcare facilities.
2. 1 July 2026 — UDI mandatory: Class III and Class IIb. Basis: TGA decision tree, When does UDI apply to my device, and F2025L00414.
3. 1 July 2027 — UDI mandatory: Class IIa. Same basis.
4. December 2027 — review of ACSQHC Advisory AS25/01 (the document states To be reviewed: December 2027).
5. 1 January 2028 — UDI dates under the EU MDD→MDR transition pathway (including implantable Class IIb); direct marking on the same day. Basis: TGA decision tree.
6. 1 April 2028 — hospital mandatory reporting Stage 2 (extended to Class IIa, IIb and III devices and Class 3 and 4 IVDs; near adverse events, 45 days). Basis: TGA hospital reporting guidance and ACSQHC AS25/01.
7. 1 July 2028 — UDI mandatory: Class Is, Class 4 IVD and Class 3 IVD. Basis: TGA decision tree.
8. 1 January 2029 — UDI and direct marking dates under the EU MDD→MDR transition pathway (non-implantable Class IIb and similar); the application submission deadline for Class 3 IVDs on the IVD side. Basis: TGA decision tree; Schedule 2 of the Information Determination.
9. 1 July 2029 — UDI mandatory: Class 2 IVD and Class 1 IVD (instruments CT943 and software CT944); the “legacy device” backstop date; certain direct marking dates. Basis: TGA decision tree.
10. 1 January 2030 — UDI under the EU IVDD→IVDR transition pathway; the application submission deadline for Class 2 IVDs. Basis: TGA decision tree; Schedule 2 of the Information Determination.
11. 1 April 2030 — hospital mandatory reporting Stage 3 (the final stage, covering “treatment”). Basis: TGA hospital reporting guidance and ACSQHC AS25/01.
12. 1 July 2030 — direct marking dates for certain pathways. Basis: TGA decision tree.
13. Strategic document: TGA, An Action Plan for Medical Devices (4 April 2019), with three directions — improving market access pathways, strengthening monitoring and follow-up of devices in use, and providing more information to patients.
14. [Practical estimate] No official source has been found confirming new IVD classification rule transition deadlines during 2027–2030, and no specific dates should be written into formal documents on this point.

3. Expert insights

Insight 1: 2026 is the year of heaviest concentration. The first UDI mandatory date (1 July) and the start of hospital mandatory reporting (21 March) fall in the same year, and both bear directly on Class III devices and Class 4 IVDs. Holders of these two product groups need to advance labelling data governance and vigilance system upgrades in parallel, with a single owner accountable for both workstreams. Class III and Class 4 IVD portfolios should be the first through both gates.

Insight 2: 2028 is the second peak. UDI extends to Class Is and Class 3 and 4 IVDs (1 July), hospital reporting enters Stage 2 (1 April), and the first UDI date under the EU transition pathway (1 January) all fall in 2028. The preparation window for mid-risk products is in effect only two years, which is why the 2028 batch should be started during 2027 rather than after the 2026 work has fully settled.

Insight 3: the “legacy device” backstop date of 1 July 2029 is the easiest to overlook. Devices manufactured before their compliance start date and still under the sponsor’s control on that date must all be compliant by then. Handling of inventory and in-transit goods must be planned in advance, otherwise the stock becomes a stranded asset that can neither be sold nor made compliant. The stocktake should distinguish stock that can be relabelled from stock that must be consumed or withdrawn.

4. Practical recommendations

• Schedule on a three-year rolling plan: in 2026 complete UDI and vigilance upgrades for Class III and IIb; in 2027 complete Class IIa and start the 2028 batch; in 2028–2029 complete the remaining classes and clear inventory.
• Build a three-column ledger of date, product and owner, and set an internal deadline six months ahead of every date, and assign a named owner to each row of the ledger.
• For the 1 July 2029 legacy device backstop, take stock of inventory and in-transit goods one year in advance and prepare a consumption or compliance plan for every stock position that will still be open on that date.
• Review this table once a year, and recalibrate after the compiled regulation is updated (usually in September) and after fee adjustments (1 July).

5. Verification checklist

• □ A three-year rolling plan covering 2026–2030 has been established
• □ The UDI and hospital reporting workstreams for 2026 are advancing in parallel
• □ The 2028 batch (Class Is, Class 3 and 4 IVD, Stage 2) has been started early
• □ An inventory stocktake for the 1 July 2029 legacy device backstop has been scheduled
• □ Two annual calibration points in July and September have been set

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Australian market. Our team manages adverse event reporting and recall coordination with the TGA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com